Sensei Biotherapeutics (NASDAQ:SNSE) Issues Earnings Results

Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) announced its quarterly earnings results on Tuesday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05), Fidelity Earnings reports.

SNSE stock traded up $0.02 during midday trading on Thursday, reaching $1.55. The company’s stock had a trading volume of 4,664 shares, compared to its average volume of 75,083. The company has a debt-to-equity ratio of 0.01, a quick ratio of 30.38 and a current ratio of 30.38. The stock has a fifty day simple moving average of $2.20 and a two-hundred day simple moving average of $4.70. Sensei Biotherapeutics has a 1 year low of $1.48 and a 1 year high of $15.12. The firm has a market capitalization of $47.56 million, a price-to-earnings ratio of -1.17 and a beta of 0.79.

In other Sensei Biotherapeutics news, Director James Peyer purchased 15,000 shares of the stock in a transaction on Thursday, February 24th. The stock was acquired at an average price of $3.63 per share, with a total value of $54,450.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Cambrian Biopharma Inc bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 14th. The shares were purchased at an average cost of $4.18 per share, with a total value of $41,800.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 66,203 shares of company stock worth $264,629.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in Sensei Biotherapeutics by 20.2% in the fourth quarter. BlackRock Inc. now owns 1,202,729 shares of the company’s stock valued at $6,975,000 after acquiring an additional 202,407 shares during the period. State Street Corp increased its position in shares of Sensei Biotherapeutics by 25.2% in the fourth quarter. State Street Corp now owns 210,292 shares of the company’s stock valued at $1,220,000 after buying an additional 42,261 shares in the last quarter. Morgan Stanley increased its position in shares of Sensei Biotherapeutics by 1,538.4% in the second quarter. Morgan Stanley now owns 107,726 shares of the company’s stock valued at $1,051,000 after buying an additional 101,151 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of Sensei Biotherapeutics in the first quarter valued at approximately $116,000. Finally, Bank of New York Mellon Corp increased its position in shares of Sensei Biotherapeutics by 155.4% in the third quarter. Bank of New York Mellon Corp now owns 47,066 shares of the company’s stock valued at $495,000 after buying an additional 28,635 shares in the last quarter. 11.10% of the stock is owned by institutional investors.

Separately, Piper Sandler lowered their target price on shares of Sensei Biotherapeutics from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, March 10th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Sensei Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $12.25.

Sensei Biotherapeutics Company Profile (Get Rating)

Sensei Biotherapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.

Further Reading